09:55 AM EST, 02/20/2025 (MT Newswires) -- Genmab ( GMAB ) said Thursday that it has received Japanese regulatory approval for its Epkinly drug for the treatment of relapsed or refractory follicular lymphoma in patients who have received two or more prior lines of therapy.

The approval from the Japan Ministry of Health, Labour and Welfare is based on results from the company's global phase 1/2 EPCORE NHL-1 and Japanese phase 1/2 EPCORE NHL-3 clinical trials, Genmab ( GMAB ) said.

Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma, accounting for 20-30% of all cases. There are 19,000 patients living with the disease in Japan right now, the company said.

Price: 22.11, Change: +0.14, Percent Change: +0.64